Stock market anomaly | Eli Lilly (LLY.US) plunges nearly 14% as the efficacy of oral weight loss drug falls short of expectations.

According to the Wisdom Finance APP, on Thursday, Eli Lilly (LLY.US) fell by nearly 14%, closing at $642.12. On the news front, a late-stage study by Lilly showed that, from a statistical perspective, their experimental oral weight loss drug orforglipron helped patients successfully lose about 11%, which is lower than Wall Street's expectations. In terms of the trial itself, taking the highest dose of orforglipron helped patients achieve an average weight loss of 12.4% over 72 weeks. At least three analysts have stated that the market originally expected orforglipron to achieve a weight loss effect similar to that of Novo Nordisk's Wegovy in 2021, which was a 14.9% reduction over 68 weeks, and some analysts even predicted that this drug's effect would surpass Novo Nordisk's popular product.